Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.
Recently, four distinct cell lines were established from patients whose malignancies had been defined by immunological and biochemical markers. Each patient had a distinct subtype of a T-cell cancer, and each possessed elevated adenosine deaminase and reduced nucleoside phosphorylase activity. Cell lines cultured in vitro possessed the same basic immunophenotype and biochemical enzyme activity as the patients' original malignant cells. In a direct comparison of the immunophenotype of the cell lines and the patients' malignant cells, full concordance existed for 48 of 52 paired antibody tests performed. However, when compared to the corresponding patient's sample, each cell line showed some minor changes in antigen expression or enzyme level. Antigen loss, de novo antigen expression, or elevated adenosine deaminase levels occurred in the cell lines, and these changes were stable on repeated analysis. While there was good general concordance between the patient's cancer and the established cell line, minor biological differences in the cell lines may reflect cellular maturation or subpopulation selection in vitro.
D000243:Adenosine Deaminase / Q000032:analysis*; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis*; D002460:Cell Line; D005434:Flow Cytometry; D006801:Humans; D007945:Leukemia, Lymphoid / Q000201:enzymology* / Q000276:immunology*; D008223:Lymphoma / Q000201:enzymology* / Q000276:immunology*; D009700:Nucleoside Deaminases / Q000032:analysis*; D010430:Pentosyltransferases / Q000032:analysis*; D011683:Purine-Nucleoside Phosphorylase / Q000032:analysis*; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D010430:Pentosyltransferases; D011683:Purine-Nucleoside Phosphorylase; D009700:Nucleoside Deaminases; D000243:Adenosine Deaminase